Hilde Gerris Krol
PARTNERPhD Medical Biology
Medical strategies, built on
the full picture.
We map rare disease ecosystems and build living evidence systems that help biotech and pharma teams make better decisions across development, medical affairs, launch and market access.
Publications
Clinical trials
Guidelines
Patients
Treatment centres
Payers
Our purpose
From scattered evidence to better decisions.
Entire ecosystem
Not just KOLs.
Clinicians, patients, treatment centres, payers and companies shaping the disease.
Broader coverage
Thousands of sources, gaps made clear.
Evidence across countries and source types, with thin areas named.
Kept current
A living evidence base, not a report that ages.
Refreshed as programmes, guidelines, competitors and markets change.
Expert-reviewed
AI expands the search, specialists validate it.
Claims stay linked to sources and key readings are reviewed by people.
How we work
Build the evidence once. Use it for every decision that follows.
One structured evidence base per disease. Not a new project for every question.
- 01
Map the disease
- 02
Validate the evidence
- 03
Add the people and system
- 04
Apply it to the decision
- 05
Keep it current
Decisions it supports
- Indication choice
- Trial and site strategy
- Country prioritisation
- KOL and centre mapping
- Evidence gaps
- Launch readiness
Team
Built by people from rare disease.
Our founding team pairs deep rare disease expertise with entrepreneurial execution and AI capability. Between us, we have worked across medical affairs, commercial strategy, scientific advisory, and AI-enabled innovation in metabolic disorders, neurological diseases, and oncology.
Jochem Bossenbroek
PARTNERMBA
Patrick de Boer
ADVISOR
Why Systemix
Specialist research for the decision ahead.
Rare disease decisions depend on understanding how the whole system works.
Rare disease is all we do
Small populations, uncertain evidence and complex care are our everyday work.
Verified by the people who shape care
We test key findings with clinicians, payers, labs, centres and patients.
Europe, country by country
Diagnosis, access and care differ by country. We analyse each market, not EU averages.
A living picture, delivered by senior people
AI widens the search. Senior partners interpret it and work with you directly.
An example of the depth
1,000+
publications screened
289
sources across 89 organisations
458
traceable claims
15
expert interviews
6 weeks
to a pre-final landscape
Illustrative figures from a recent European Batten disease landscape.
See client resultsHow clients can work with us
Start with the decision. Build an evidence base that lasts beyond it.
Intelligence starting point
Consulting
Focused research around one strategic decision. Delivered in weeks.
- Rare disease landscaping
- TPP validation
- Barrier and driver analysis
- Country prioritisation
Ongoing intelligence
Living Intelligence
The evidence base stays current after the project. We track what changes and refresh the picture.
- Therapy and diagnostic monitoring
- New clinical evidence
- Guideline and regulatory changes
- Competitive intelligence
Auditable by design
Every finding stays linked to its source and version.
Example claim record
- Claim
- “From 13 January 2028, EU joint clinical assessments also apply to orphan medicinal products.”
- Checked
- 2 November 2026
- Version
- 1
- Confidence
- High (legal text)
Example for illustration. Every claim in a client deliverable carries these fields.
Bring us in early.
Tell us about the therapy, diagnostic or disease area you want to bring to patients. We will help you understand where the evidence is strong, where the gaps are and what you need to know next.